{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T05:39:31Z","timestamp":1768801171182,"version":"3.49.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T00:00:00Z","timestamp":1694995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cancer Center Support"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Stool pathogen testing is recommended as part of the initial evaluation for patients with new-onset diarrhea on immune checkpoint inhibitors (ICIs), yet its significance has not been well-studied. We aimed to determine the impact of multiplex gastrointestinal (GI) pathogen PCR testing on the clinical course and use of immunosuppressive therapy in patients who develop diarrhea on ICIs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This retrospective cohort included individuals who underwent GI pathogen panel PCR for diarrhea on ICIs at Memorial Sloan Kettering between 7\/2015 and 7\/2021. The primary outcome was use of immunosuppressive therapy for suspected immunotherapy-related enterocolitis (irEC). Secondary outcomes included diarrhea severity and endoscopic and histologic disease patterns.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 521 ICI-treated patients tested for GI pathogens, 61 (11.7%) had a positive PCR. Compared to patients without detectable infections, patients with infections had more frequent grades 3-4 diarrhea (37.7% vs. 19.6%, P &amp;lt; .01) and colitis (39.3% vs. 14.7%, P &amp;lt; .01). However, patients with infections did not have higher rates of persistent or recurrent diarrhea and were less likely to receive steroids (P &amp;lt; .01) and second-line immunosuppressive agents (P = .03). In 105 patients with lower endoscopy, similar trends were observed and no differences in endoscopic severity or histologic patterns were noted between groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>GI infections in ICI-treated patients presenting with diarrhea are linked to more severe but self-limited clinical presentations and may be optimally treated with observation and supportive care alone. Routine and timely stool pathogen testing may help avert unnecessary empiric immunosuppression for suspected irEC, which has been linked to blunted antitumor responses and numerous adverse effects.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyad226","type":"journal-article","created":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T14:45:25Z","timestamp":1695048325000},"page":"36-46","source":"Crossref","is-referenced-by-count":5,"title":["Prevalence of Enteric Infections in Patients on Immune Checkpoint Inhibitors and Impact on Management and Outcomes"],"prefix":"10.1093","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2083-3398","authenticated-orcid":false,"given":"Patrick T","family":"Magahis","sequence":"first","affiliation":[{"name":"M.D. Program, Weill Cornell Medical College of Cornell University , New York, NY , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5497-2476","authenticated-orcid":false,"given":"Deepika","family":"Satish","sequence":"additional","affiliation":[{"name":"Gastroenterology, Hepatology, and Nutrition Service, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ngolela","family":"Esther Babady","sequence":"additional","affiliation":[{"name":"Infectious Diseases, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY , USA"},{"name":"Clinical Microbiology Service, Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center , New York, NY , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mini","family":"Kamboj","sequence":"additional","affiliation":[{"name":"Infectious Diseases, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY , USA"},{"name":"Clinical Microbiology Service, Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center , New York, NY , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A","family":"Postow","sequence":"additional","affiliation":[{"name":"M.D. Program, Weill Cornell Medical College of Cornell University , New York, NY , USA"},{"name":"Melanoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6816-3293","authenticated-orcid":false,"given":"Monika","family":"Laszkowska","sequence":"additional","affiliation":[{"name":"M.D. Program, Weill Cornell Medical College of Cornell University , New York, NY , USA"},{"name":"Gastroenterology, Hepatology, and Nutrition Service, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8245-9653","authenticated-orcid":false,"given":"David M","family":"Faleck","sequence":"additional","affiliation":[{"name":"M.D. Program, Weill Cornell Medical College of Cornell University , New York, NY , USA"},{"name":"Gastroenterology, Hepatology, and Nutrition Service, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,9,18]]},"reference":[{"key":"2024010523410707200_CIT0001","first-page":"1384","article-title":"AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: expert review","volume-title":"Gastroenterology","author":"Dougan","year":"2021"},{"key":"2024010523410707200_CIT0002","first-page":"1393","article-title":"Management of patients with immune checkpoint inhibitor-induced enterocolitis: a systematic review","volume-title":"Clin Gastroenterol Hepatol","author":"Collins","year":"2020"},{"key":"2024010523410707200_CIT0003","first-page":"662","article-title":"Management considerations for immune checkpoint inhibitor-induced enterocolitis based on management of inflammatory bowel disease","volume-title":"Inflamm Bowel Dis","author":"Abu-Sbeih","year":"2020"},{"key":"2024010523410707200_CIT0004","first-page":"207","article-title":"Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way","volume-title":"Br J Cancer","author":"Cheung","year":"2020"},{"key":"2024010523410707200_CIT0005","first-page":"230","article-title":"NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020","volume-title":"J Natl Compr Canc Netw","author":"Thompson","year":"2020"},{"key":"2024010523410707200_CIT0006","first-page":"95","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume-title":"J ImmunoTher Cancer","author":"Puzanov","year":"2017"},{"key":"2024010523410707200_CIT0007","first-page":"111","article-title":"FilmArray\u2122 GI panel performance for the diagnosis of acute gastroenteritis or hemorrhagic diarrhea","volume-title":"BMC Microbiol","author":"Piralla","year":"2017"},{"key":"2024010523410707200_CIT0008","first-page":"382","article-title":"Comparison of multiplex gastrointestinal pathogen panel and conventional stool testing for evaluation of diarrhea in patients with inflammatory bowel diseases","volume-title":"Dig Dis Sci","author":"Ahmad","year":"2019"},{"key":"2024010523410707200_CIT0009","first-page":"1034","article-title":"Enteric infection in relapse of inflammatory bowel disease: the utility of stool microbial PCR testing","volume-title":"Inflamm Bowel Dis","author":"Axelrad","year":"2017"},{"key":"2024010523410707200_CIT0010","first-page":"135","article-title":"The characteristics of nivolumab-induced colitis: an evaluation of three cases and a literature review","volume-title":"BMC Gastroenterol","author":"Yamauchi","year":"2018"},{"key":"2024010523410707200_CIT0011","first-page":"150","article-title":"The significance of histological activity measurements in immune checkpoint inhibitor colitis","volume-title":"Aliment Pharmacol Ther","author":"Pai","year":"2021"},{"key":"2024010523410707200_CIT0012","first-page":"1665","article-title":"Detection of gastrointestinal pathogens in oncology patients by highly multiplexed molecular panels","volume-title":"Eur J Clin Microbiol Infect Dis","author":"Otto","year":"2017"},{"key":"2024010523410707200_CIT0013","first-page":"3706","article-title":"High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma","volume-title":"Cancer","author":"Faje","year":"2018"},{"key":"2024010523410707200_CIT0014","first-page":"2268","article-title":"Association of anti-TNF with decreased survival in steroid refractory ipilimumab and anti-PD1-treated patients in the Dutch melanoma treatment registry","volume-title":"Clin Cancer Res","author":"Verheijden","year":"2020"},{"key":"2024010523410707200_CIT0015","first-page":"3","article-title":"Gastrointestinal and hepatic complications of immune checkpoint inhibitors","volume-title":"Curr Gastroenterol Rep","author":"Cramer","year":"2017"},{"key":"2024010523410707200_CIT0016","first-page":"1530","article-title":"Enteric infections are common in patients with flares of inflammatory bowel disease","volume-title":"Am J Gastroenterol","author":"Axelrad","year":"2018"},{"key":"2024010523410707200_CIT0017","first-page":"3287","article-title":"Prevalence and effect of intestinal infections detected by a PCR-based stool test in patients with inflammatory bowel disease","volume-title":"Dig Dis Sci","author":"Limsrivilai","year":"2020"},{"key":"2024010523410707200_CIT0018","first-page":"402","article-title":"Outcomes of immune checkpoint inhibitor-related diarrhea or colitis in cancer patients with superimposed gastrointestinal infections","volume-title":"Am J Clin Oncol","author":"Ma","year":"2021"},{"key":"2024010523410707200_CIT0019","first-page":"95","article-title":"Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis","volume-title":"J ImmunoTher Cancer","author":"Abu-Sbeih","year":"2018"},{"key":"2024010523410707200_CIT0020","first-page":"1695","article-title":"Endoscopic and histologic features of immune checkpoint inhibitor-related colitis","volume-title":"Inflamm Bowel Dis","author":"Wang","year":"2018"},{"key":"2024010523410707200_CIT0021","first-page":"836","article-title":"Clinical, endoscopic, and histologic characteristics of ipilimumab-associated colitis","volume-title":"Clin Gastroenterol Hepatol","author":"Verschuren","year":"2016"},{"key":"2024010523410707200_CIT0022","first-page":"e000451","article-title":"Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis","volume-title":"J ImmunoTher Cancer","author":"Mooradian","year":"2020"},{"key":"2024010523410707200_CIT0023","first-page":"e000278","article-title":"Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management","volume-title":"ESMO Open","author":"Geukes Foppen","year":"2018"},{"key":"2024010523410707200_CIT0024","first-page":"1229","article-title":"Interferon-gamma-producing CD8(+) tissue resident memory T cells are a targetable hallmark of immune checkpoint inhibitor-colitis","volume-title":"Gastroenterology","author":"Sasson","year":"2021"},{"key":"2024010523410707200_CIT0025","first-page":"655","article-title":"Molecular pathways of colon inflammation induced by cancer immunotherapy","volume-title":"Cell","author":"Luoma","year":"2020"},{"key":"2024010523410707200_CIT0026","first-page":"242","article-title":"Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis","volume-title":"J ImmunoTher Cancer","author":"Abu-Sbeih","year":"2019"},{"key":"2024010523410707200_CIT0027","first-page":"91","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume-title":"Science","author":"Routy","year":"2018"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/1\/36\/55119320\/oyad226.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/1\/36\/55119320\/oyad226.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T23:44:30Z","timestamp":1704498270000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/29\/1\/36\/7276456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,18]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,9,18]]},"published-print":{"date-parts":[[2024,1,5]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyad226","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1,1]]},"published":{"date-parts":[[2023,9,18]]}}}